期刊
JOURNAL OF CHEMOTHERAPY
卷 35, 期 5, 页码 383-396出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/1120009X.2022.2121091
关键词
Remdesivir; COVID-19; mortality; oxygen support; length of stay; time to clinical improvement
This study conducted a systematic review with meta-analysis and found that Remdesivir did not significantly improve survival in COVID-19 patients receiving standard therapy, but it could significantly reduce the duration of oxygen support.
Remdesivir (RDV) is a broad-spectrum antiviral drug, now approved by Regulatory Agencies for COVID-19 treatment. RDV is associated with improvements in clinical outcomes, but no conclusive studies have shown an effect in reducing mortality. This study aimed to carry out a systematic review with meta-analysis to investigate whether RDV can significantly modify the outcome of COVID-19 patients evaluating its effects on mortality, length of stay, time to clinical improvement and need for oxygen supplementation. No significant improvement in terms of survival in patients treated with standard therapy (ST)+RDV as compared to ST alone (P = 0.24) was found. The duration of oxygen support was significantly lower in patients treated with ST + RDV compared with ST alone (P = 0.03). Further investigations should be planned to assess the real impact of RDV in the management of COVID-19 patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据